Maija Lahtela-Kakkonen
Senior Researcher
Adjunct Professor Drug Design
School of Pharmacy, Faculty of Health Sciences
maija.lahtela-kakkonen@uef.fi | +358 40 355 3692
We are studying epigenetic regulators involved in histone acetylation. We use drug design methods for identifying novel inhibitors and activators, and study their impact with in vitro assays and in various cell lines. We are focused on class III histodecatylases (HDACs) and Bromodomains (BRDs). In addition we are identifying novel compounds for various other targets such as prolyloligopeptidase (POP, PREP) and TRPA1, latter is linked in neuropathic pain. We are also modeling transporters and microplastics.
Research groups
Publications
77 items-
Micro-sized polyethylene particles affect cell viability and oxidative stress responses in human colorectal adenocarcinoma Caco-2 and HT-29 cells
Herrala, Mikko; Huovinen, Marjo; Järvelä, Essi; Hellman, Julia; Tolonen, Pauliina; Lahtela-Kakkonen, Maija; Rysä, Jaana. 2023. Science of the total environment. 867: -
SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors
Djokovic, Nemanja; Rahnasto-Rilla, Minna; Lougiakis, Nikolaos; Lahtela-Kakkonen, Maija; Nikolic, Katarina. 2023. Pharmaceuticals. 16: -
Apteekin toiminnan kehittäminen toimintakäsikirjan ja työryhmätaulukon avulla
Honkanen, Marko; Kangas, Saana; Niskanen, Merja; Vainio, Kirsti; Sepponen, Kati; Lahtela-Kakkonen, Maija . 2022. Dosis. 38: 362-381 -
Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics
Djokovic, Nemanja; Ruzic, Dusan; Rahnasto-Rilla, Minna; Srdic-Rajic, Tatjana; Lahtela-Kakkonen, Maija; Nikolic, Katarina. 2022. Journal of chemical information and modeling. 62: 2571-2585 -
PE and PET oligomers’ interplay with membrane bilayers
Järvenpää, Joni; Perkkiö, Milla; Laitinen, Riikka; Lahtela-Kakkonen, Maija. 2022. Scientific reports. 12: . 2234 -
Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines
Järvenpää, Joni; Rahnasto-Rilla, Minna; Lahtela-Kakkonen, Maija; Küblbeck, Jenni. 2022. Biomedicine and pharmacotherapy. 147: -
2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors
Pätsi, Henri T.; Kilpeläinen, Tommi P.; Auno, Samuli; Dillemuth, Pyry M. J.; Arja, Khaled; Lahtela-Kakkonen, Maija K.; Myöhänen, Timo T.; Wallén, Erik A. A.. 2021. Acs medicinal chemistry letters. 12: 1578-1584 -
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, Outi MH; Alanko, Ida; Bhadane, Rajendra; Bonvin, Alexandre MJJ; Honorato, Rodrigo Vargas; Hossain, Shakhawath; Juffer, André H; Kabedev, Aleksei; Lahtela-Kakkonen, Maija; Larsen, Anders Støttrup; Lescrinier, Eveline; Marimuthu, Parthiban; Mirza, Muhammad Usman; Mustafa, Ghulam; Nunes-Alves, Ariane; Pantsar, Tatu; Saadabadi, Atefeh; Singaravelu, Kalaimathy; Vanmeert, Michiel. 2021. Processes. 9: 71 -
Recent Advances on Molecular Modeling Studies of Transient Receptor Potential Ankyrin 1
Sallomy, Carita; Lahtela-Kakkonen, Maija; Timonen, Juri M. 2021. Medicine research. 5: 200021 -
Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells
Tenhunen, Jonna; Kucera, Tomá¨; Huovinen, Marjo; Küblbeck, Jenni; Bisenieks, Egils; Vigante, Brigita; Ogle, Zaiga; Duburs, Gunars; Dole¸al, Martin; Moaddel, Ruin; Lahtela-Kakkonen, Maija; Rahnasto-Rilla, Minna. 2021. Biomedicine and pharmacotherapy. 138: 111452